Novera Dihexa

Dihexa is an experimental compound with potential neurotrophic properties, originally developed as a synthetic peptide derivative of angiotensin IV. Researchers have studied it primarily for its proposed action on hepatocyte growth factor (HGF) and MET receptor pathways, examining endpoints such as synaptic density, dendritic spine formation, and spatial memory performance in rodent models. Laboratories looking to buy dihexa peptide for controlled experiments will find it categorized alongside other angiotensin-derived tool compounds used to probe neurobiology and neuroplasticity.

Novera Dihexa is supplied strictly for laboratory research use only. It is not FDA-approved for human use, carries no therapeutic indication, and must not be administered to humans or animals outside controlled research protocols. Dihexa is sold strictly as a research chemical, and all orders are restricted to licensed professionals conducting in vitro or in vivo investigations. There are no established clinical trials for Dihexa, and its proposed cognitive benefits remain unverified in human trials.

What Novera Dihexa Is

Dihexa is a peptidomimetic derived from the N-terminal tripeptide fragment of norleucine-angiotensin IV. Where the parent compound angiotensin IV degrades rapidly in plasma and crosses the blood-brain barrier poorly, the compound’s designers replaced C-terminal residues with hexanoic acid and 6-aminohexanoic acid. These lipophilic modifications produce a molecule that is more resistant to enzymatic breakdown in rodent serum and, in preclinical work, reaches central nervous system compartments after oral dosing in rats (McCoy et al., 2013, Journal of Pharmacology and Experimental Therapeutics, a paper that has carried a formal expression of concern since 2021).

The structural changes also shift the molecule’s pharmacological profile away from classical AT4/IRAP binding associated with angiotensin IV, redirecting activity toward pathways involving hepatocyte growth factor signaling. This makes Dihexa useful as a reference material when researchers need a stable, brain-penetrant tool compound to study synaptogenesis, neuroplasticity, and HGF-dependent signaling in cell culture or animal research models.

Why Researchers Study Dihexa

Published science on this molecule concentrates on HGF and MET receptor pathways, which are important in cellular growth and survival, as well as downstream cascades including PI3K/Akt and MAPK signaling. Preclinical studies show Dihexa’s effects on hepatocyte growth factor signaling, with endpoints ranging from c-Met phosphorylation in neuronal cultures to expression of synaptic proteins such as synaptophysin and PSD-95 in rodent brain tissue.

Current evidence consists almost entirely of in vitro and rodent data. No peer-reviewed human trial results have been published as of October 2026. The subsections below organize the compound’s research literature by application area: cognition models, synaptic plasticity, neurodegeneration, proposed mechanism, and preclinical tolerability.

Cognition And Memory Models

Spatial learning and memory tasks form the most examined endpoint category for this peptide in laboratory research. McCoy et al. reported in 2013 (Journal of Pharmacology and Experimental Therapeutics, 344(1), 141-154) that an orally active, blood-barrier permeant analog, N-hexanoic-Tyr-Ile-(6) aminohexanoic amide, reversed scopolamine-induced deficits in rat Morris water maze performance and showed activity in an aged-rat model. That paper has carried a formal expression of concern since 2021, so the individual doses, latencies and effect sizes reported in it cannot be treated as reliable.

The one recent study untouched by the retraction record is Martino et al. (2025, Neurotrauma Reports, 6(1), 991-998), which used a closed-head midline impact model of mild traumatic brain injury in rodents and found that an HGF/MET positive modulator rescued working memory deficits dose-dependently after repeated injury.

“Following repeated mild TBI, the HGF/MET-positive modulator dose-dependently rescued the working memory deficits following injury.” Martino et al., 2025, Neurotrauma Reports.

These findings do not establish direct evidence for cognitive effects in humans. They are hypothesis-generating observations from rodent models that require independent replication and, eventually, controlled human trials before any conclusions about human cognition can be drawn.

Synaptic Plasticity And Neurobiology

HGF/c-Met signaling has been studied in the context of synaptogenesis because c-Met receptor activation can trigger downstream cascades that influence dendritic spine formation and synaptic protein expression in neurons. The picomolar dendritic-spine and miniature-EPSC data usually quoted for this compound come from Benoist et al. (2014, Journal of Pharmacology and Experimental Therapeutics, 351(2), 390-402), which was retracted in April 2025. Nothing equivalent has been reproduced in the surviving literature.

Uribe et al. (2015, Frontiers in Cellular Neuroscience, 9, 3) tested whether the compound protected larval zebrafish lateral line hair cells from neomycin and gentamicin. A concentration of 1 µM gave optimal protection, and that protection was partially attenuated by inhibitors of the downstream HGF targets Akt, TOR and MEK. Two of the four authors also appear on the retracted Washington State series, so this is not an independent replication. These are mechanistic observations in a fish preparation, not evidence of therapeutic benefit.

Neurodegeneration And Injury Models

Several groups have examined Dihexa in rodent models that mimic aspects of neurodegenerative or injury-related pathology. Sun et al. published a 2021 study in Brain Sciences (11(11), 1487) using APP/PS1 transgenic mice, an Alzheimer’s-type model. Animals received the compound orally at 1.44 or 2.88 mg/kg/day for three months (n=6 per group). Treated mice showed increased neuronal counts by Nissl staining in cortex, elevated synaptophysin expression, and reduced pro-inflammatory cytokines IL-1β and TNF-α compared with untreated controls, alongside increased anti-inflammatory IL-10. Morris water maze performance also improved, with more platform crossings and shorter latency versus vehicle-treated APP/PS1 mice.

In APP/PS1 transgenic mice, Sun et al. (2021, Brain Sciences) reported increased neuronal cells and SYP protein expression on Nissl staining, reduced activation of astrocytes and microglia, markedly lower IL-1β and TNF-α and higher IL-10 relative to controls.

Not all disease models showed benefit. Wells et al. (2024, Journal of Huntington’s Disease, 13(1), 55-66) randomised forty male Wistar rats into vehicle, 3-nitropropionic acid, and 3-NP plus PNB-0408 groups, tracked body weight, motor function and cognition for five weeks, then ran histopathology. The compound did not protect the animals from any of the deficits 3-NP produced.

No disease-modifying effect has been established in humans. All neuropathology data remain confined to laboratory models.

HGF/c-Met Signaling Mechanism

The proposed mechanism for this compound centers on modulation of the hepatocyte growth factor/c-Met receptor system. Early work claimed Dihexa bound HGF with a dissociation constant (KD) of approximately 65 picomolar and potentiated HGF dimerization, enhancing c-Met phosphorylation at subthreshold ligand concentrations. However, the foundational paper describing that binding interaction, Benoist et al. (2014, Journal of Pharmacology and Experimental Therapeutics, 351(2), 390-402), was retracted in April 2025; the retraction notice is Journal of Pharmacology and Experimental Therapeutics, 392(4), 103567. The specific affinity values and the claim that c-Met knockdown fully blocked the compound’s effects are therefore no longer considered reliable.

“Dihexa activated the PI3K/AKT signaling pathway, while PI3K inhibitor wortmannin significantly reversed the anti-inflammatory and anti-apoptotic effects” Sun et al., 2021, Brain Sciences.

Surviving, non-retracted evidence from the APP/PS1 mouse study (Sun et al., 2021) shows that this molecule increased PI3K expression and phosphorylated Akt in treated animals, and that the PI3K inhibitor wortmannin reversed the compound’s anti-inflammatory and anti-apoptotic effects. These data implicate the PI3K/Akt pathway downstream of whatever upstream receptor interaction occurs. Independent confirmation of direct HGF binding or of the specific c-Met activation profile has not appeared in the non-flagged literature. Questions about off-target interactions, receptor redundancy, and potential engagement of other growth factor pathways remain open.

Preclinical Safety And Tolerability

No dedicated chronic toxicology study, genotoxicity analysis, carcinogenicity assessment, or reproductive toxicity evaluation has been published for Dihexa. Safety observations come incidentally from behavioral and efficacy studies. Neither of the two non-retracted in vivo reports, Sun et al. (2021, Brain Sciences) in APP/PS1 mice and Martino et al. (2025, Neurotrauma Reports) in a mild traumatic brain injury model, was designed as a safety study, and neither publishes mortality, body-weight or organ-level toxicity data that could stand in for one.

Theoretical risks associated with Dihexa include oncogenic risks, because HGF and MET receptor pathways are well characterized drivers of cell proliferation and metastasis in cancer biology. With the mechanistic binding claims now retracted, formal risk assessment is speculative but not dismissible. There is no established human safety profile.

How Dihexa Compares With Related Compounds

Researchers selecting a tool compound for HGF/c-Met or angiotensin-related studies often weigh Dihexa against the endogenous peptide angiotensin IV or against small-molecule c-Met modulators that bypass the angiotensin scaffold entirely. The table below compares these options on target profile, evidence base, and common research applications.

A researcher might select Novera Dihexa over angiotensin IV when the experimental question concerns synaptogenesis or HGF-pathway engagement rather than classical renin-angiotensin outputs like blood flow regulation. Angiotensin IV degrades rapidly in serum and penetrates the blood-brain barrier poorly, limiting its utility in chronic oral dosing paradigms. For groups focused on translational relevance or validated mechanism, small-molecule c-Met modulators with established binding data may be preferable, particularly given that the retraction of the Benoist et al. paper has left Dihexa’s exact receptor-level interaction uncertain. Selection ultimately depends on desired pathway specificity, pharmacokinetics in the chosen model species, and whether the study requires a compound with a well-characterized safety profile.

What Research On Dihexa Does Not Establish

Interest in this compound has grown in recent years, but the gap between what is claimed online and what peer-reviewed, non-retracted publications support is substantial. Several categories of claims lack published evidence.

No human efficacy, safety, or pharmacokinetic data exist. Dihexa is not FDA-approved for human use, and no registered prospective human trial for PNB-0408 versus placebo in any disease has been published as of October 2026. Claims of definitive human cognitive enhancement or disease modification that circulate on forums and vendor sites have no basis in the peer-reviewed literature.

Much of the foundational literature has been withdrawn. In April 2025 the Journal of Pharmacology and Experimental Therapeutics retracted three papers from the Washington State group: Kawas et al. 2011 (JPET, 339, 509-518, “Mimics of the Dimerization Domain of Hepatocyte Growth Factor Exhibit Anti-Met and Anticancer Activity”), Kawas et al. 2012 (JPET, 340, 539-548, “Development of Angiotensin IV Analogs as Hepatocyte Growth Factor/Met Modifiers”) and Benoist et al. 2014 (JPET, 351(2), 390-402). The three retraction notices are JPET, 392(4), 103568, 103566 and 103567. A fourth paper, McCoy et al. 2013 (JPET, 344(1), 141-154), has carried a formal expression of concern since 2021. The core mechanistic claim, that this compound binds HGF with picomolar affinity and depends on c-Met activation, rests on Benoist 2014 and is therefore withdrawn, and the potency comparisons built on it, “seven orders of magnitude” or “ten million times more potent than BDNF“, now have no surviving source.

“PNB-0408 did not protect rats from the deficits induced by 3-NP neurotoxicity.” Wells et al., 2024, Journal of Huntington’s Disease.

Negative preclinical results also exist: in a 2024 Huntington’s-disease rat model using 3-nitropropionic acid toxicity, Dihexa failed to protect motor behavior or histopathological endpoints across five weeks of treatment. Not all animal models show benefit.

No formal toxicology program (carcinogenicity, genotoxicity, reproductive or developmental toxicity) has been conducted. Because HGF/c-Met is a proto-oncogenic pathway, long-term safety questions are not merely academic. Novera Dihexa is not an approved therapy and should be treated strictly as an experimental research tool, appropriate only for controlled laboratory research.

Where to Buy Novera Dihexa

Qualified laboratories looking for where to buy dihexa peptide for HGF/c-Met pathway studies or neurobiology research can order Novera Dihexa through this store. Orders for dihexa peptide buy online are fulfilled under the following terms:

• Estimated delivery time 3 to 7 days.

• Free shipping on orders over $750.

• All US import fees and tariffs are covered by Ogomed, so the buyer pays nothing extra; customs checks under the new US import rules can add a little time to delivery.

• Price match: if the same product is listed for less elsewhere, Ogomed will try to match it.

• Support by phone +1-650-457-5621 and email, 10am to 6pm EST.

• Sold to licensed professionals, for laboratory research use only.

Novera Dihexa is supplied only to licensed professionals for controlled laboratory research applications. It is strictly labeled for laboratory or research use only, not for clinical, veterinary, or at-home use.

References

1. McCoy, A. T., Benoist, C. C., Wright, J. W., et al. (2013). Evaluation of metabolically stabilized angiotensin IV analogs as procognitive/antidementia agents. Journal of Pharmacology and Experimental Therapeutics, 344(1), 141-154. DOI: 10.1124/jpet.112.199497 (Expression of Concern, 2021)
2. Benoist, C. C., Kawas, L. H., Zhu, M., et al. (2025). Retraction notice to “The Procognitive and Synaptogenic Effects of Angiotensin IV-Derived Peptides Are Dependent on Activation of the Hepatocyte Growth Factor/c-Met System” [J Pharmacol Exp Ther 351 (2014) 390-402]. Journal of Pharmacology and Experimental Therapeutics, 392(4), 103567. DOI: 10.1016/j.jpet.2025.103567
3. Sun, X., Deng, Y., Fu, X., Wang, S., Duan, R., Zhang, Y. (2021). AngIV-Analog Dihexa Rescues Cognitive Impairment and Recovers Memory in the APP/PS1 Mouse via the PI3K/AKT Signaling Pathway. Brain Sciences, 11(11), 1487. DOI: 10.3390/brainsci11111487
4. Martino, K. A., Nakhre, A., Demarest, R. M., Devilbiss, D. M. (2025). Hepatocyte Growth Factor/MET Activator Rescues Working Memory Deficits after Repeated Mild Traumatic Brain Injury. Neurotrauma Reports, 6(1), 991-998. DOI: 10.1177/2689288X251392851
5. Wells, R. G., Azzam, A. F., Hiller, A. L., Sardinia, M. F. (2024). Effects of an Angiotensin IV Analog on 3-Nitropropionic Acid-Induced Huntington’s Disease-Like Symptoms in Rats. Journal of Huntington’s Disease, 13(1), 55-66. DOI: 10.3233/JHD-231507
6. Uribe, P. M., Kawas, L. H., Harding, J. W., Coffin, A. B. (2015). Hepatocyte growth factor mimetic protects lateral line hair cells from aminoglycoside exposure. Frontiers in Cellular Neuroscience, 9, 3. DOI: 10.3389/fncel.2015.00003